Format

Send to

Choose Destination
Front Immunol. 2014 Feb 24;5:74. doi: 10.3389/fimmu.2014.00074. eCollection 2014.

Armed therapeutic viruses - a disruptive therapy on the horizon of cancer immunotherapy.

Author information

1
Bayer HealthCare, US Innovation Center, Biologics Research , San Francisco, CA , USA.

Abstract

For the past 150 years cancer immunotherapy has been largely a theoretical hope that recently has begun to show potential as a highly impactful treatment for various cancers. In particular, the identification and targeting of immune checkpoints have given rise to exciting data suggesting that this strategy has the potential to activate sustained antitumor immunity. It is likely that this approach, like other anti-cancer strategies before it, will benefit from co-administration with an additional therapeutic and that it is this combination therapy that may generate the greatest clinical outcome for the patient. In this regard, oncolytic viruses are a therapeutic moiety that is well suited to deliver and augment these immune-modulating therapies in a highly targeted and economically advantageous way over current treatment. In this review, we discuss the blockade of immune checkpoints, how oncolytic viruses complement and extend these therapies, and speculate on how this combination will uniquely impact the future of cancer immunotherapy.

KEYWORDS:

CTLA-4; PD1; PDL1; PDL2; blockade of checkpoint inhibitors; cancer immunotherapy; immune-checkpoint inhibitors; oncolytic virus

Supplemental Content

Full text links

Icon for Frontiers Media SA Icon for PubMed Central
Loading ...
Support Center